MarketPeel
Insider Trading Intelligence
BD

Backer Marianne De

ARWR
DIRECTOR · ARROWHEAD PHARMACEUTICALS, INC. · CIK 0001797819
FILING MIX · LIFETIME68%/32%
BUYS
25
SELLS
12
TOTAL VALUE
$3.19M
COMPANIES
2
ACTIVE SINCE
Jan 2020
HOLDINGS NOW
719,206
AVG SELL PX
$10.55
TRADE KIND
SHOWING 37 / 37
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
19 backtested trades · 8 horizons · 12 pending
Forward-return performance of every backtestable P/S trade by Backer Marianne De, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d19+68.42%-2.51%-1.07%-1.44%-5.09%
14d19+68.42%-0.20%-1.53%+1.33%-2.16%
30d19+63.16%+5.82%+0.88%+4.94%+0.56%
60d19+73.68%+4.74%+3.77%+0.97%+8.09%
90d19(1 pending)+77.78%+4.21%+7.76%-4.30%-9.19%
180d19(3 pending)+93.75%+10.35%+14.55%-4.20%+1.39%
1y19(3 pending)+87.50%+64.82%+25.19%+39.63%+29.05%
2y19(5 pending)+78.57%+2.87%+36.77%-33.90%-36.82%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ARWR · 4,593 shares · as of Jan 10, 2023
07,81715,63423,45031,2672020202120222023SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 25 buys / 12 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
VIR
VIR BIOTECHNOLOGY, INC.
PURCHASE
President and CEO
233,532286,650Apr 29, 2026Apr 30, 2026View →
VIR
VIR BIOTECHNOLOGY, INC.
SALE
President and CEO
233,532714,613Apr 29, 2026Apr 30, 2026View →
VIR
VIR BIOTECHNOLOGY, INC.
SALE10b5-1
10b5-1 plan
72,559$9.16$664.4K948,145Apr 6, 2026Apr 7, 2026View →
VIR
VIR BIOTECHNOLOGY, INC.
SALE10b5-1
10b5-1 plan
14,762$9.53$140.7K1,020,704Feb 24, 2026Feb 26, 2026View →
VIR
VIR BIOTECHNOLOGY, INC.
SALE10b5-1
10b5-1 plan
19,039$7.45$141.9K1,035,466Feb 23, 2026Feb 24, 2026View →
VIR
VIR BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
285,0001,054,505Feb 22, 2026Feb 24, 2026View →
VIR
VIR BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
570,000570,000Feb 22, 2026Feb 24, 2026View →
VIR
VIR BIOTECHNOLOGY, INC.
SALE10b5-1
10b5-1 plan
79,712$5.95$474.2K769,505Apr 3, 2025Apr 4, 2025View →
VIR
VIR BIOTECHNOLOGY, INC.
SALE10b5-1
10b5-1 plan
16,122$9.45$152.4K849,217Feb 24, 2025Feb 25, 2025View →
VIR
VIR BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
480,000480,000Feb 22, 2025Feb 25, 2025View →
VIR
VIR BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
240,000865,339Feb 22, 2025Feb 25, 2025View →
VIR
VIR BIOTECHNOLOGY, INC.
SALE
Chief Executive Officer
53,118625,339Jun 12, 2024Jun 12, 2024View →
VIR
VIR BIOTECHNOLOGY, INC.
PURCHASE
Chief Executive Officer
53,11853,118Jun 12, 2024Jun 12, 2024View →
VIR
VIR BIOTECHNOLOGY, INC.
SALE10b5-1
10b5-1 plan
72,995$9.46$690.4K678,457Apr 3, 2024Apr 4, 2024View →
VIR
VIR BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
175,000751,452Feb 22, 2024Feb 26, 2024View →
VIR
VIR BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
350,000350,000Feb 22, 2024Feb 26, 2024View →
VIR
VIR BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
576,452576,452Apr 3, 2023Apr 4, 2023View →
VIR
VIR BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
1,152,9041,152,904Apr 3, 2023Apr 4, 2023View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
7,86731,267Jan 10, 2023Jan 11, 2023View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
4,5934,593Jan 10, 2023Jan 11, 2023View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
6,40023,400Jan 7, 2022Jan 7, 2022View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
SALE
272$66.25$18.0K17,000Jan 3, 2022Jan 4, 2022View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
SALE
2,244$64.25$144.2K19,256Jan 3, 2022Jan 4, 2022View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
SALE
1,984$65.01$129.0K17,272Jan 3, 2022Jan 4, 2022View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
SALE
5,000$89.85$449.3K21,500Jun 24, 2021Jun 25, 2021View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
9,00026,500Jan 1, 2021Jan 5, 2021View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
PURCHASE
500$50.93$25.5K17,000Oct 8, 2020Oct 26, 2020View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
PURCHASE
500$50.00$25.0K17,500Oct 8, 2020Oct 26, 2020View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
PURCHASE
500$31.33$15.7K16,500Jun 15, 2020Jun 24, 2020View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
PURCHASE
500$35.40$17.7K16,000Apr 15, 2020Jun 24, 2020View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
PURCHASE
500$23.94$12.0K15,500Mar 16, 2020Jun 24, 2020View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
PURCHASE
500$24.80$12.4K15,000Mar 12, 2020Jun 24, 2020View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
PURCHASE
500$28.60$14.3K14,500Mar 11, 2020Jun 24, 2020View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
PURCHASE
500$34.39$17.2K14,000Feb 28, 2020Jun 24, 2020View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
PURCHASE
500$35.07$17.5K13,500Feb 27, 2020Jun 24, 2020View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
PURCHASE
500$54.95$27.5K13,000Jan 13, 2020Jun 24, 2020View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
7,50012,500Jan 1, 2020Jan 3, 2020View →
Other insiders · ARWR
Loading peer insiders…
About this filer
CIK 0001797819
ROLE
Director
PRIMARY
ARWR
COMPANIES
2
ACTIVE SINCE
Jan 2020
MARKETPEEL · /INSIDER/0001797819DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback